<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01094093</url>
  </required_header>
  <id_info>
    <org_study_id>20080767</org_study_id>
    <nct_id>NCT01094093</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of AMG 139 following&#xD;
      single subcutaneous (SC) or intravenous (IV) dose administration in healthy subjects and&#xD;
      subjects with moderate to severe psoriasis (PsO).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 11, 2010</start_date>
  <completion_date type="Actual">July 26, 2011</completion_date>
  <primary_completion_date type="Actual">July 26, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety &amp; tolerability: treatment-emergent AEs including clinically significant changes in physical examinations, safety lab tests, ECG, vital signs, or immunogenicity to AMG 139</measure>
    <time_frame>16-24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterization of the pharmacokinetics (PK) of AMG 139</measure>
    <time_frame>16-24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Activity and Severity Index (PASI) scores (Part B only)</measure>
    <time_frame>16-24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four dose levels of AMG 139 administered as a single dose SC or IV in subjects with moderate-severe psoriasis (Part B).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 139</intervention_name>
    <description>Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers (Part A) and subjects with moderate-severe psoriasis (Part B).</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Part A - Healthy Volunteers:&#xD;
&#xD;
          -  Healthy male or female of non-reproductive potential subjects between 18 to 45&#xD;
             years-of-age&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 32 kg/m2&#xD;
&#xD;
          -  Normal or clinically acceptable physical examination, clinical laboratory values, and&#xD;
             ECG&#xD;
&#xD;
          -  Additional inclusion criteria apply&#xD;
&#xD;
        Part B - Psoriasis Subjects:&#xD;
&#xD;
          -  Male or female of non-reproductive potential subjects with PsO between 18 to 55&#xD;
             years-of-age&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 32 kg/m2&#xD;
&#xD;
          -  Normal or clinically acceptable physical examination (PE), clinical laboratory values,&#xD;
             and ECG; clinically acceptable PE includes evidence of moderate to severe plaque PsO&#xD;
&#xD;
          -  Diagnosis of plaque PsO for at least 6 months&#xD;
&#xD;
          -  Moderate to severe plaque PsO defined by:&#xD;
&#xD;
          -  A minimum PASI score of ≥ 10&#xD;
&#xD;
          -  Psoriasis involving ≥ 10% of the Body Surface Area (BSA)&#xD;
&#xD;
          -  Additional inclusion criteria apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Parts A - Healthy Volunteers:&#xD;
&#xD;
          -  History or evidence of a clinically significant disorder (including psychiatric),&#xD;
             condition or disease that would pose a risk to subject safety or interfere with the&#xD;
             study evaluation, procedures or completion;&#xD;
&#xD;
          -  Recent or on-going infection(s)&#xD;
&#xD;
          -  Underlying condition(s) that predisposes the subject to infections&#xD;
&#xD;
          -  History of malignancy of any type, other than in situ cervical cancer or surgically&#xD;
             excised non-melanomatous skin cancers in past 5 years&#xD;
&#xD;
          -  Additional exclusion criteria apply&#xD;
&#xD;
        Part B - Psoriasis Subjects:&#xD;
&#xD;
          -  History or evidence of a clinically significant disorder (including psychiatric),&#xD;
             condition or disease that would pose a risk to subject safety or interfere with the&#xD;
             study evaluation, procedures or completion;&#xD;
&#xD;
          -  Recent or on-going infection(s)&#xD;
&#xD;
          -  Underlying condition(s) that predisposes the subject to infections&#xD;
&#xD;
          -  Guttate, pustular, or other non-plaque forms of PsO&#xD;
&#xD;
          -  Evidence of skin conditions other than PsO (eg, eczema) that would interfere with&#xD;
             evaluations of the effect of investigational product on psoriasis&#xD;
&#xD;
          -  History of malignancy of any type, other than in situ cervical cancer or surgically&#xD;
             excised non-melanomatous skin cancers in past 5 years&#xD;
&#xD;
          -  Additional exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nucleus Network Limited</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Medical and Analytical eXcellence (CMAX)</name>
      <address>
        <city>Adelaide</city>
        <zip>SA500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QPharm Pty Limited</name>
      <address>
        <city>Herston</city>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies Ltd</name>
      <address>
        <city>Grafton</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 25, 2010</study_first_submitted>
  <study_first_submitted_qc>March 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2010</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amgen</keyword>
  <keyword>AMG 139</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

